Historically, the main approaches to slow CKD progression have been improved control of the inciting disease state, primarily hypertension, and/or utilizing the nephroprotective benefits of ACEi/ARBs. However, there is now evidence supporting use/FDA approval for SGLT2 inhibitors in the setting of slowing CKD progression. This presentation will review this literature, places in therapy of these agents, and clinical implications of these therapies.
- Provider:Ascension
- Activity Link: https://ascension-ce-cme.cloud-cme.com/default.aspx
- Start Date: 2024-02-26 06:00:00
- End Date: 2024-02-26 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABS - 1.0 Point; Credit Type(s): Accredited CME (ABS)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Variable
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: General Surgery
Subscribe
Login
0 Comments
Oldest